scholarly journals Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus

2013 ◽  
Vol 2 (1) ◽  
pp. 22 ◽  
Author(s):  
H Naik ◽  
J Lu ◽  
C Cao ◽  
M Pfister ◽  
M Vakilynejad ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
The Novel ◽  
Dose Selection ◽  
Selection Of

scholarly journals The Novel Compound Sul-121 Preserves Endothelial Function and Inhibits Progression of Kidney Damage in Type 2 Diabetes Mellitus in Mice

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
S. P. H. Lambooy ◽  
A. Bidadkosh ◽  
D. Nakladal ◽  
A. van Buiten ◽  
R. A. T. Girgis ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Endothelial Function ◽  
Kidney Damage ◽  
The Novel

New emerging roles of the novel hepatokine SERPINB1 in type 2 diabetes mellitus: crosstalk with β-cell dysfunction and dyslipidemia

2020 ◽  
Author(s):  
Mohamed Mostafa Kamal ◽  
Aya Adel ◽  
Ghada Hussein Sayed ◽  
Shadia Ragab ◽  
Dina Hamada Kassem
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
The Novel ◽  
Β Cell ◽  
Cell Dysfunction

DPP-4 inhibitors and hypoglycemia in the patients with type 2 diabetes mellitus

2013 ◽  
Vol 59 (5) ◽  
pp. 72-80
Author(s):  
Iu Sh Khalimov
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Adverse Events ◽  
Clinical Condition ◽  
Hypoglycemic Agents ◽  
The Novel ◽  
Oral Hypoglycemic Agents ◽  
Novel Approaches

The incidence of hypoglycemia remains rather high among the population of patients with type 2 diabetes mellitus (DM2) especially in those treated with the traditional oral hypoglycemic agents. Hypoglycemia is one of the most frequent adverse events encountered by a physician dealing with diabetic (DM2) patients. At the same time, the novel approaches are currently available that allow this clinical condition to be avoided.

scholarly journals Current Management of Type 2 Diabetes Mellitus: What to Pay Attention to in Outpatient Settings

Doctor Ru ◽  
2021 ◽  
Vol 20 (2) ◽  
pp. 40-44
Author(s):  
N.A. Chernikova ◽  
◽  
O.A. Knyshenko ◽  
◽  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Combined Therapy ◽  
Individual Characteristics ◽  
Antihyperglycemic Agents ◽  
Number Of Patients ◽  
Antihyperglycemic Therapy ◽  
Selection Of

Objective of the Review: To discuss the problem of selecting antihyperglycemic drugs; to identify the trends in prescription of various groups of oral antihyperglycemic agents. Key Points. When type 2 diabetes mellitus (DM2) is diagnosed, a number of patients need prompt combined antihyperglycemic therapy because of a marked carbohydrate metabolism disorder. The prescription paradigm of initial therapy has shifted towards antihyperglycemic agents with established nephro- and cardioprotective effects (sodium-glucose linked transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists). Drugs are recommended depending on presence or absence of a comorbid cardiovascular disease (CVD) and cardiovascular risk factors, and safety as regards hypoglycaemic events; therefore, very often selection of a therapeutic regimen can be challenging. Still, the first-line treatment for patients without CVD is metformin; however, a combined therapy is required in the majority of cases. Poor compliance, continued use of monotherapy, despite the need to boost the therapy, patient’s reluctance to take additional drugs can facilitate occurrence and progression of a lot of associated complications. In such cases, combined medications reducing the amount of tablets and improving compliance are useful. The most common combination of antihyperglycemic drugs is metformin and sulfonylureas. Still, care should be taken because of differences in pharmacokinetics and pharmacodynamics of the molecules in the latter group. High selectivity of some sulfonylureas can evidence their milder effect for glucose level reduction. Sulfonylureas are also cost-effective as compared to other antidiabetic medications. Conclusion. A wide choice of drugs allows a medical professional selecting an optimal antihyperglycemic regimen, taking into account individual characteristics of a patient. Prompt combined medications are a treatment of choice for the majority of patients with DM. Selection of antihyperglycemic drugs is affected by the cost as well. The most important thing is that the drugs are well-studied, efficient and safe. Keywords: type 2 diabetes mellitus, combined therapy, sulphonylurea, Glimepiride, metformin.

scholarly journals Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association

Circulation ◽  
2020 ◽  
Vol 141 (19) ◽  
Author(s):  
Suzanne V. Arnold ◽  
Deepak L. Bhatt ◽  
Gregory W. Barsness ◽  
Alexis L. Beatty ◽  
Prakash C. Deedwania ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Type 2 Diabetes Mellitus ◽  
Coronary Artery ◽  
Cardiovascular Outcomes ◽  
Artery Disease ◽  
Selection Of

Although cardiologists have long treated patients with coronary artery disease (CAD) and concomitant type 2 diabetes mellitus (T2DM), T2DM has traditionally been considered just a comorbidity that affected the development and progression of the disease. Over the past decade, a number of factors have shifted that have forced the cardiology community to reconsider the role of T2DM in CAD. First, in addition to being associated with increased cardiovascular risk, T2DM has the potential to affect a number of treatment choices for CAD. In this document, we discuss the role that T2DM has in the selection of testing for CAD, in medical management (both secondary prevention strategies and treatment of stable angina), and in the selection of revascularization strategy. Second, although glycemic control has been recommended as a part of comprehensive risk factor management in patients with CAD, there is mounting evidence that the mechanism by which glucose is managed can have a substantial impact on cardiovascular outcomes. In this document, we discuss the role of glycemic management (both in intensity of control and choice of medications) in cardiovascular outcomes. It is becoming clear that the cardiologist needs both to consider T2DM in cardiovascular treatment decisions and potentially to help guide the selection of glucose-lowering medications. Our statement provides a comprehensive summary of effective, patient-centered management of CAD in patients with T2DM, with emphasis on the emerging evidence. Given the increasing prevalence of T2DM and the accumulating evidence of the need to consider T2DM in treatment decisions, this knowledge will become ever more important to optimize our patients’ cardiovascular outcomes.

Sign in / Sign up

Export Citation Format

Share Document